StreetInsider.com News Articles

Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's

Mon, 19 Oct 2026 08:01:07 -0400

Johnson & Johnson (NYSE: JNJ) announced one-year results from its Phase 3 FUZION study showing that Tremfya (guselkumab) maintained or improved fistula remission through 48 weeks in adults with Crohn's disease with perianal fistula. The findings were presented at the 2026 United European Gastroenterology Week.

Among patients receiving Tremfya 100 mg every 8 weeks, combined fistula remission — defined as complete closure of all external fistula openings with no drainage and no evidence of underlying fluid collections on MRI — increased from 28% at Week 24 to 35% at Week 48. Results among patients receiving Tremfya 200 mg every 4 weeks

Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's

Mon, 19 Oct 2026 08:01:07 -0400

Johnson & Johnson's Tremfya shows fistula remission at 48 weeks in Crohn's

Mon, 19 Oct 2026 08:01:07 -0400

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

Mon, 19 Oct 2026 08:00:00 -0400

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group
These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized,

Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

Mon, 19 Oct 2026 08:00:00 -0400

TREMFYA maintained combined fistula remission through Week 48 across both maintenance dose regimens, including an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group

These findings build on the Phase 3 clinical program, demonstrating efficacy in a dedicated, randomized,

Johnson & Johnson (JNJ) PT Raised to $287 at Wells Fargo

Fri, 16 Oct 2026 06:24:00 -0400
Wells Fargo analyst Larry Biegelsen raised the price target on Johnson & Johnson (NYSE: JNJ) to $287.00 (from $275.00) while maintaining a Overweight rating.

Johnson & Johnson (JNJ) PT Raised to $270 at Bernstein SocGen Group

Thu, 15 Oct 2026 08:27:04 -0400

Bernstein SocGen Group analyst Lee Hambright raised the price target on Johnson & Johnson (NYSE: JNJ) to $270.00 (from $261.00) while maintaining a Market Perform rating.
The analyst commented: "Bullish outlook; but FY27 EPS reset; Yesterday before the open, JNJ reported a solid Q3, with 6.1% organic sales growth and a 3% EPS beat. Innovative Medicine strength and U.S. momentum offset a ~1.5% MedTech miss driven by international headwinds and Abiomed weakness. Management nudged up FY26 guidance and remains confident in double-digit sales growth by the end of the decade, though FY27 EPS growth could be flattish due to (1) a

Johnson & Johnson (JNJ) PT Raised to $270 at Bernstein SocGen Group

Thu, 15 Oct 2026 08:27:04 -0400

Bernstein SocGen Group analyst Lee Hambright raised the price target on Johnson & Johnson (NYSE: JNJ) to $270.00 (from $261.00) while maintaining a Market Perform rating.
The analyst commented: "Bullish outlook; but FY27 EPS reset; Yesterday before the open, JNJ reported a solid Q3, with 6.1% organic sales growth and a 3% EPS beat. Innovative Medicine strength and U.S. momentum offset a ~1.5% MedTech miss driven by international headwinds and Abiomed weakness. Management nudged up FY26 guidance and remains confident in double-digit sales growth by the end of the decade, though FY27 EPS growth could be flattish due to (1) a

Johnson & Johnson (JNJ) PT Lowered to $292 at Morgan Stanley

Thu, 15 Oct 2026 08:19:35 -0400
Morgan Stanley analyst Terrance Flynn lowered the price target on Johnson & Johnson (NYSE: JNJ) to $292.00 (from $294.00) while maintaining a Overweight rating.

Johnson & Johnson (JNJ) PT Lowered to $280; RBC Capital: 'Excessive Sell-Off Creates Defensive Opportunity'

Wed, 14 Oct 2026 08:54:42 -0400

RBC Capital analyst Trung Huynh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $280.00 (from $290.00) while maintaining a Outperform rating.
The analyst commented: "Excessive Sell-Off Creates Defensive Opportunity Ahead of December EBR; JNJ shares fell ~6% today despite delivering in-line results and raising guidance. While we view the sell-off as excessive, it sets a negative tone for the broader Pharma sector and underscores the heightened volatility in today's market, particularly for crowded long positions. That said, JNJ's strong growth fundamentals remain intact, even if near-term upside appears limited post-3Q26. We continue to view JNJ as a quality

Johnson & Johnson (JNJ) PT Lowered to $280; RBC Capital: 'Excessive Sell-Off Creates Defensive Opportunity'

Wed, 14 Oct 2026 08:54:42 -0400

RBC Capital analyst Trung Huynh lowered the price target on Johnson & Johnson (NYSE: JNJ) to $280.00 (from $290.00) while maintaining a Outperform rating.
The analyst commented: "Excessive Sell-Off Creates Defensive Opportunity Ahead of December EBR; JNJ shares fell ~6% today despite delivering in-line results and raising guidance. While we view the sell-off as excessive, it sets a negative tone for the broader Pharma sector and underscores the heightened volatility in today's market, particularly for crowded long positions. That said, JNJ's strong growth fundamentals remain intact, even if near-term upside appears limited post-3Q26. We continue to view JNJ as a quality

Johnson & Johnson (JNJ) PT Lowered to $275 at Wells Fargo

Wed, 14 Oct 2026 05:40:53 -0400
Wells Fargo analyst Larry Biegelsen lowered the price target on Johnson & Johnson (NYSE: JNJ) to $275.00 (from $282.20) while maintaining a Overweight rating.

Johnson & Johnson (JNJ) PT Raised to $275 at BofA Securities

Wed, 14 Oct 2026 05:15:48 -0400
BofA Securities analyst Jason M. Gerberry raised the price target on Johnson & Johnson (NYSE: JNJ) to $275.00 (from $262.00) while maintaining a Neutral rating.

Form 8-K JOHNSON & JOHNSON For: Oct 13

Tue, 13 Oct 2026 08:13:00 -0400
si-local-file:///var/storage/secattach/20261013/27177624.html

Johnson & Johnson beats estimates, raises 2026 guidance

Tue, 13 Oct 2026 06:55:35 -0400

Investing.com -- Johnson & Johnson (NYSE: JNJ) reported its latest quarterly results ahead of the open on Tuesday, exceeding analyst expectations.

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

The company raised its full-year 2026 guidance, now projecting adjusted EPS of $11.05-$11.15, compared to the analyst consensus of $11.08. Revenue guidance was increased to $101.0-$101.4 billion, with the $101.2 billion midpoint matching the consensus estimate of $101.4 billion.

Shares rose 0.1% following the announcement.

"Johnson &

Johnson & Johnson beats estimates, raises 2026 guidance

Tue, 13 Oct 2026 06:55:35 -0400

Investing.com -- Johnson & Johnson (NYSE: JNJ) reported its latest quarterly results ahead of the open on Tuesday, exceeding analyst expectations.

Adjusted earnings per share of $2.59 beat the consensus estimate of $2.53 by $0.06. Revenue reached $25.4 billion, slightly above the $25.38 billion consensus, representing a 5.9% increase from $24.0 billion in the same quarter last year.

The company raised its full-year 2026 guidance, now projecting adjusted EPS of $11.05-$11.15, compared to the analyst consensus of $11.08. Revenue guidance was increased to $101.0-$101.4 billion, with the $101.2 billion midpoint matching the consensus estimate of $101.4 billion.

Shares rose 0.1% following the announcement.

"Johnson &

Johnson & Johnson (JNJ) Declares $1.34 Quarterly Dividend; 2% Yield

Tue, 13 Oct 2026 06:25:03 -0400

Johnson & Johnson (NYSE: JNJ) declared a quarterly dividend of $1.34 per share, or $5.36 annualized.

The dividend will be payable on December 8, 2026, to stockholders of record on November 24, 2026, with an ex-dividend date of November 23, 2026.

The annual yield on the dividend is 2 percent.

For a dividend history and other dividend-related data on Johnson & Johnson (JNJ) click here.

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

Tue, 13 Oct 2026 06:25:00 -0400

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

Tue, 13 Oct 2026 06:25:00 -0400

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company’s common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are

Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast

Tue, 13 Oct 2026 06:21:35 -0400

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.59, $0.06 better than the analyst estimate of $2.53. Revenue for the quarter came in at $25.4 billion versus the consensus estimate of $25.38 billion.
GUIDANCE:
Johnson & Johnson sees FY2026 EPS of $10.95-$11.05, versus the consensus of $11.08. Johnson & Johnson sees FY2026 revenue of $101-101.4 billion, versus the consensus of $101.4 billion.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

Johnson & Johnson (JNJ) Tops Q3 EPS by 6c; adjusts forecast

Tue, 13 Oct 2026 06:21:35 -0400

Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.59, $0.06 better than the analyst estimate of $2.53. Revenue for the quarter came in at $25.4 billion versus the consensus estimate of $25.38 billion.
GUIDANCE:
Johnson & Johnson sees FY2026 EPS of $10.95-$11.05, versus the consensus of $11.08. Johnson & Johnson sees FY2026 revenue of $101-101.4 billion, versus the consensus of $101.4 billion.
For earnings history and earnings-related data on Johnson & Johnson (JNJ) click here.

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

Tue, 13 Oct 2026 06:20:00 -0400

2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*

2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals

Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint

Significant

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

Tue, 13 Oct 2026 06:20:00 -0400

2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1%*

2026 Third-Quarter earnings per share (EPS) of $0.09 reflects a one-time special charge for the proposed talc litigation resolution, the acquisition of Firefly Bio, Inc., and the strategic collaboration with Sail Biomedicines; adjusted EPS* of $2.59 also reflects the impact of these M&A deals

Strong operational performance results in the Company increasing 2026 guidance with estimated reported sales of $101.2 Billion or 7.4% at the midpoint and increasing adjusted EPS* guidance by $0.06 to $11.10 or 2.9% at the midpoint

Significant

JNJ earnings preview Q3: weaker profit expected as biotech deals weigh

Tue, 13 Oct 2026 00:00:00 -0400

Investing.com-- Johnson & Johnson is set to report its third quarter earnings before the market open on October 13, with the pharmaceutical giant expected to post a softer profit due to costs tied to two recent biotech deals.
The healthcare conglomerate is expected to post adjusted EPS of $2.54, down from $2.80 a year earlier, on revenue of $25.38 billion, up from $23.99 billion, according to Investing.com forecasts.
J&J said on July 29 it had completed its acquisition of Firefly Bio, which is developing cancer-focused degrader antibody conjugates, and entered strategic agreements with Sail Biomedicines, which is working on in

JNJ earnings preview Q3: weaker profit expected as biotech deals weigh

Tue, 13 Oct 2026 00:00:00 -0400

Investing.com-- Johnson & Johnson is set to report its third quarter earnings before the market open on October 13, with the pharmaceutical giant expected to post a softer profit due to costs tied to two recent biotech deals.
The healthcare conglomerate is expected to post adjusted EPS of $2.54, down from $2.80 a year earlier, on revenue of $25.38 billion, up from $23.99 billion, according to Investing.com forecasts.
J&J said on July 29 it had completed its acquisition of Firefly Bio, which is developing cancer-focused degrader antibody conjugates, and entered strategic agreements with Sail Biomedicines, which is working on in